MRI-Derived Radiomics to Guide Post-operative Management for High-Risk Prostate Cancer

被引:45
作者
Bourbonne, Vincent [1 ,2 ,3 ]
Vallieres, Martin [2 ,4 ]
Lucia, Francois [1 ,2 ,3 ]
Doucet, Laurent [5 ]
Visvikis, Dimitris [2 ]
Tissot, Valentin [6 ]
Pradier, Olivier [1 ,2 ,3 ]
Hatt, Mathieu [2 ]
Schick, Ulrike [1 ,2 ,3 ]
机构
[1] Univ Hosp, Dept Radiat Oncol, Brest, France
[2] Brest Univ, LaTIM, INSERM, UMR 1101, Brest, France
[3] Univ Bretagne Occidentale, Brest, France
[4] McGill Univ, Med Phys Unit, Montreal, PQ, Canada
[5] Univ Hosp, Dept Anatomopathol, Brest, France
[6] Univ Hosp, Dept Radiol, Brest, France
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词
magnetic resonance imaging; prostatic neoplasms; radiomics; machine learning; treatment failure; SALVAGE RADIATION-THERAPY; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; RADIOTHERAPY; PREDICTION; SURVIVAL; FEATURES; OUTCOMES;
D O I
10.3389/fonc.2019.00807
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Prostatectomy is one of the main therapeutic options for prostate cancer (PCa). Studies proved the benefit of adjuvant radiotherapy (aRT) on clinical outcomes, with more toxicities when compared to salvage radiotherapy. A better assessment of the likelihood of biochemical recurrence (BCR) would rationalize performing aRT. Our goal was to assess the prognostic value of MRI-derived radiomics on BCR for PCa with high recurrence risk. Methods: We retrospectively selected patients with a high recurrence risk (T3a/b or T4 and/or R1 and/or Gleason score>7) and excluded patients with a post-operative PSA > 0.04 ng/mL or a lymph-node involvement. We extracted IBSI-compliant radiomic features (shape and first order intensity metrics, as well as second and third order textural features) from tumors delineated in T2 and ADC sequences. After random division (training and testing sets) and machine learning based feature reduction, a univariate and multivariate Cox regression analysis was performed to identify independent factors. The correlation with BCR was assessed using AUC and prediction of biochemical relapse free survival (bRFS) with a Kaplan-Meier analysis. Results: One hundred seven patients were included. With a median follow-up of 52.0 months, 17 experienced BCR. In the training set, no clinical feature was correlated with BCR. One feature from ADC (SZE(GLSZM)) outperformed with an AUC of 0.79 and a HR 17.9 (p = 0.0001). Lower values of SZE(GLSZM) are associated with more heterogeneous tumors. In the testing set, this feature remained predictive of BCR and bRFS (AUC 0.76, p = 0.0236). Conclusion: One radiomic feature was predictive of BCR and bRFS after prostatectomy helping to guide post-operative management.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Optimizing the Management of High-Risk, Localized Prostate Cancer
    Sundi, Debasish
    Jeong, Byong Chang
    Lee, Seung Bae
    Han, Misop
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (12) : 815 - 820
  • [22] Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance
    Sushentsev, Nikita
    Rundo, Leonardo
    Blyuss, Oleg
    Nazarenko, Tatiana
    Suvorov, Aleksandr
    Gnanapragasam, Vincent J.
    Sala, Evis
    Barrett, Tristan
    EUROPEAN RADIOLOGY, 2022, 32 (01) : 680 - 689
  • [23] Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer
    Bratt, Ola
    Folkvaljon, Yasin
    Eriksson, Marie Hjalm
    Akre, Olof
    Carlsson, Stefan
    Drevin, Linda
    Lissbrant, Ingela Franck
    Makarov, Danil
    Loeb, Stacy
    Stattin, Par
    EUROPEAN UROLOGY, 2015, 68 (01) : 53 - 58
  • [24] Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance
    Nikita Sushentsev
    Leonardo Rundo
    Oleg Blyuss
    Tatiana Nazarenko
    Aleksandr Suvorov
    Vincent J Gnanapragasam
    Evis Sala
    Tristan Barrett
    European Radiology, 2022, 32 : 680 - 689
  • [25] Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy
    Franzese, Ciro
    Cozzi, Luca
    Badalamenti, Marco
    Baldaccini, Davide
    D'Agostino, Giuseppe
    Fogliata, Antonella
    Navarria, Pierina
    Franceschini, Davide
    Comito, Tiziana
    Clerici, Elena
    Reggiori, Giacomo
    Tomatis, Stefano
    Scorsetti, Marta
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (08) : 710 - 718
  • [26] Post-operative Radiation Therapy for Prostate Cancer Still no genomic Risk Profiling for clinical Routine
    Finazzi, Tobias
    Zimmermann, Frank
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (01) : 70 - 72
  • [27] Advances in the management of high-risk localised and metastatic prostate cancer
    Bellmunt, Joaquim
    Attard, Gerhardt
    Bahl, Amit
    Huland, Hartwig
    Klotz, Laurence
    Kuban, Deborah
    Oudard, Stephane
    Watson, William
    BJU INTERNATIONAL, 2012, 109 : 8 - 13
  • [28] Management of High-Risk Localised Prostate Cancer
    Ozen, Haluk
    Yazici, Sertac
    Inci, Kubilay
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (05) : 439 - 447
  • [29] High-risk prostate cancer: treat the prostate
    Cooperberg, Matthew R.
    LANCET, 2011, 378 (9809) : 2056 - 2057
  • [30] Quantitative breast MRI radiomics for cancer risk assessment and the monitoring of high-risk populations
    Mendel, Kayla R.
    Li, Hui
    Giger, Maryellen L.
    MEDICAL IMAGING 2016: COMPUTER-AIDED DIAGNOSIS, 2015, 9785